Rotigotine

Download image
Mode of action
Rotigotine
Transporter zone
No interaction
Enzyme zone
No interaction
Receptor zone
Important for clinical effects
Contributes to other effects
Contributes to other effects
Ion channel zone
No interaction
References
  1. Fox SH, Katzenschlager R, Lim SY, et al. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord 26 Suppl 3: S2-41.
  2. Kulisevsky J and Pagonabarraga J. (2010) Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf 33: 147-161.
  3. Scheller D, Ullmer C, Berkels R, et al. (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 379: 73-86.
  4. Seeman P. (2015) Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69: 183-189.

For more detailed explanation of the principles of the VM Library

Please notice that Caution should be applied when extrapolating animal data to humans.

Detailed and Approved Information on the clinical use of the compounds can be found at the homepage of EMA or at Martindale.

Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind